Prestige Brands "cautiously optimistic" for FY2011
This article was originally published in The Tan Sheet
Executive Summary
Higher sales of Clear Eyes, Murine and Compound W were offset by declines in Chloraseptic, Little Remedies and Allergen Block products during Prestige Brands Holdings' fourth quarter. Net sales were essentially flat for the Irvington, N.Y., firm, though the settlement of an intellectual property lawsuit regarding a Prestige OTC brand contributed to a reported $3.6 million in "other revenues" during the quarter. Prestige said May 13 its OTC segment generated net revenues of $42.6 million, up 7.1 percent, in the January-March period, while total revenues climbed 4 percent to $71.4 million. Fourth-quarter net income from continuing operations reached $3.3 million, compared to a net loss of $211.1 million a year ago, which reflected a substantial impairment charge. For fiscal 2010, Prestige's consolidated net sales dipped 1.3 percent to $296.9 million, with $32.1 million in net income. President and CEO Matthew Mannelly said the company enters fiscal 2011 with an air of "cautious optimism," based on the sales momentum of its core OTC brands and the "compelling marketing plans" developed for them. However, he acknowledged comparable-store sales growth remains a challenge for Prestige products as consumer spending stagnates
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.